Gillmore, J. D., Judge, D. P., Cappelli, F., Fontana, M., Garcia-Pavia, P., Gibbs, S., … ATTRibute-CM Investigators. (2025). A plain language review of the ATTRibute-CM study: efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. Future Cardiol, 21(12), 1017–1025. https://doi.org/10.1080/14796678.2025.2591426

Gillmore, Julian D., Daniel P. Judge, Francesco Cappelli, Marianna Fontana, Pablo Garcia-Pavia, Simon Gibbs, Martha Grogan, et al. “A plain language review of the ATTRibute-CM study: efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy.” Future Cardiol 21, no. 12 (December 2025): 1017–25. https://doi.org/10.1080/14796678.2025.2591426.

Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. A plain language review of the ATTRibute-CM study: efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. Future Cardiol. 2025 Dec;21(12):1017–25.

Gillmore, Julian D., et al. “A plain language review of the ATTRibute-CM study: efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy.” Future Cardiol, vol. 21, no. 12, Dec. 2025, pp. 1017–25. Pubmed, doi:10.1080/14796678.2025.2591426.

Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, Grogan M, Hanna M, Hoffman J, Masri A, Maurer MS, Nativi-Nicolau J, Obici L, Poulsen SH, Rockhold F, Shah KB, Soman P, Garg J, Chiswell K, Xu H, Cao X, Lystig T, Sinha U, Fox JC, ATTRibute-CM Investigators. A plain language review of the ATTRibute-CM study: efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. Future Cardiol. 2025 Dec;21(12):1017–1025.